The team, from biopharmaceutical company Regeneron, hopes their work will help researchers better understand protein-protein interactions during preclinical development of a drug. “Essentially, we ...
In a different type of signaling event, the scientists fused the binding proteins to a newly designed nanopore, a protein ...